EGFR p.L858R
About
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Dacomitinib | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Erlotinib | |
| FDA (1) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Gefitinib | |
| FDA (3) HC (3) | EGFR p.L858R | Non-Small Cell Lung Cancer | Osimertinib | |
| FDA (1) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Cisplatin, Osimertinib, Pemetrexed | |
| FDA (1) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Carboplatin, Osimertinib, Pemetrexed | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| FDA (2) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| FDA (1) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Datopotamab deruxtecan |